EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab By Ogkologos - October 23, 2025 300 0 Facebook Twitter Google+ Pinterest WhatsApp It adopted a new route for administration along with a new pharmaceutical form Source RELATED ARTICLESMORE FROM AUTHOR Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength MOST POPULAR ESMO Welcomes EU Proposals for MFF & FP10 and Calls for... July 21, 2025 Durvalumab Extends Lives of People with Early-Stage Small Cell Lung Cancer June 25, 2024 Efficacy and Safety of Patritumab Deruxtecan in Patients with EGFR-mutated NSCLC... September 29, 2023 Healthy 33-Year-Old Nurse Learned She Had Cervical Cancer and Breast Cancer... April 30, 2019 Load more HOT NEWS Cross-Border Network of European Specialists Provides New Treatment Options For Women... MAP Congress 2020: Molecular Analysis for Precision Oncology When Breast Cancer Patient Comes Into His Shop, Barber Shaves His... Celebrating 75 years of NHS cancer care
